20 12 is listed in the United States, but the price in the United States is relatively expensive, nearly 4000 dollars a month. Therefore, the ACR guidelines in the United States have just started as the third-line treatment of biological agents, but with the feedback of later application, the European and American guidelines have recommended tofacitib as the second-line recommendation after traditional drug treatment. In China, the lowest price in the world is 1.995 yuan/box, and the treatment cost is far lower than that of biological agents. In addition, after 8 years of experience, its efficacy and safety are not inferior to those of biological agents, and it is more convenient to take orally, so it has great application prospects in China, but it must be screened before use (excluding tuberculosis and hepatitis B).
Tofatib was first approved for use in the United States on 20 12, and has been approved for use in more than 50 countries around the world.
Tofatib has been recommended by many international guidelines for the treatment of rheumatoid arthritis, including the European Union against Rheumatism (EULAR), American Rheumatology Association (ACR) and Asia-Pacific Rheumatology Association (APLAR). Besides RA, it has a good research and development prospect in the treatment of many autoimmune diseases such as ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and systemic lupus erythematosus.
On March 2017 16, Pfizer announced that China Food and Drug Administration had officially approved the marketing application of Pfizer's oral JAK inhibitor tofacib (XELJANZ, Shang Jie). Tofati is approved in China for the treatment of moderate to severe active rheumatoid arthritis in adults who have insufficient efficacy or are intolerant to methotrexate. It can be used in combination with methotrexate or other abiotic antirheumatic drugs (DMARD).
Tofatib is a small molecule targeted drug, which has been approved for the treatment of rheumatoid arthritis in China, opening up a new way for the treatment of rheumatoid arthritis patients.